Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)

INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Trials using delta-9-tetrahydrocannabinol-rich (THC) products demonstrate limited antiemetic effect, significant adverse event...

Descripción completa

Detalles Bibliográficos
Autores principales: Mersiades, Antony J, Tognela, Annette, Haber, Paul S, Stockler, Martin, Lintzeris, Nicholas, Simes, John, McGregor, Iain, Olver, Ian, Allsop, David J, Gedye, Craig, Kirby, Adrienne C, Morton, Rachael L, Fox, Peter, Clarke, Stephen, Briscoe, Karen, Aghmesheh, Morteza, Wong, Nicole, Walsh, Anna, Hahn, Carmel, Grimison, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144412/
https://www.ncbi.nlm.nih.gov/pubmed/30209152
http://dx.doi.org/10.1136/bmjopen-2017-020745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144412/
https://www.ncbi.nlm.nih.gov/pubmed/30209152
http://dx.doi.org/10.1136/bmjopen-2017-020745

Ejemplares similares